Abstract
Objective We want to identify seizure onset zone (SOZ) from interictal EEG biomarkers. We hypothesize that a combination of interictal EEG biomarkers, including a novel low frequency marker, can predict mesial temporal involvement and can assist in prognosis related to surgical resections.
Methods Interictal direct current wide bandwidth invasive EEG recordings from 83 patients implanted with 5,111 electrodes were retrospectively studied. Logistic regression was used to classify electrodes and patient outcomes. A feed-forward neural network was implemented to understand putative mechanisms.
Results Interictal infraslow frequency EEG activity was decreased for SOZ electrodes while faster frequencies such as delta (2-4 Hz) and beta-gamma (20-50 Hz) activity were increased. These spectral changes comprised a novel interictal EEG biomarker that was significantly increased for mesial temporal SOZ electrodes compared to non-SOZ electrodes. Interictal EEG biomarkers correctly classified mesial temporal SOZ electrodes with a specificity of 87% and positive predictive value of 80%. These interictal EEG biomarkers also correctly classified patient outcomes after surgical resection with a specificity of 91% and positive predictive value of 87%.
Interpretation Interictal infraslow EEG activity is decreased near the SOZ while higher frequency power is increased, suggesting distinct underlying physiologic mechanisms. Decreased interictal infraslow activity may reflect the loss of neural inhibition. Narrowband interictal EEG power bands provide information about the SOZ and can help predict mesial temporal involvement in seizure onset. Together with interictal epileptiform discharges and high frequency oscillations, these interictal biomarkers may provide prognostic information prior to surgical resection.
Competing Interest Statement
BNL, BB, and GW are named inventors for intellectual property developed at Mayo Clinic and licensed to Cadence Neuroscience Inc. BNL has waived contractual rights to royalties. GW has licensed intellectual property developed at Mayo Clinic to NeuroOne, Inc. GW and BNL are investigators for the 18 Medtronic Deep Brain Stimulation Therapy for Epilepsy Post-Approval Study (EPAS). BNL, BB, and GW are investigators for Mayo Clinic and Medtronic NIH Public Private Partnership (UH3-NS95495). GW assisted in a Mayo Clinic Medtronic sponsored FDA-IDE for the investigational Medtronic Activa PC+S device.
Funding Statement
Research was support by NIH NINDS K23NS112339 (BNL) and R01NS92882 (GW).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This retrospective analysis was approved by the Mayo Clinic Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
De-identified data are available upon request.
